Generic Name and Formulations:
Nelarabine 250mg/50mL; soln for IV infusion.
Novartis Pharmaceuticals Corp
Indications for ARRANON:
T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) that is unresponsive or has relapsed after ≥2 chemotherapy regimens.
Give by IV infusion over 2hrs. 1500mg/m2 on days 1, 3, and 5; repeat every 21 days. In clinical trials, treatment was generally continued until there was evidence of disease progression, patient experienced unacceptable toxicity, patient became a candidate for bone marrow transplant, or patient no longer continued to benefit from treatment. See full labeling.
Give by IV infusion over 1hr. 650mg/m2 daily for 5 consecutive days; repeat every 21 days. In clinical trials, treatment was generally continued until there was evidence of disease progression, patient experienced unacceptable toxicity, patient became a candidate for bone marrow transplant, or patient no longer continued to benefit from treatment. See full labeling.
Neurologic adverse reactions.
Monitor closely for neurotoxicity; discontinue if ≥Grade 2 occurs. Prior or concurrent intrathecal chemotherapy or craniospinal irradiation (increased risk of neurotoxicity). May delay dosing if other toxicities occur (eg, hematologic toxicity). Monitor CBCs, platelet counts regularly, and for signs of infection. Moderate-to-severe renal or severe hepatic impairment; monitor. Ensure adequate hydration. Consider allopurinol for patients at risk for hyperuricemia. Elderly. Embryo-fetal toxicity. Use effective contraception during therapy and for 3 months (males) after last dose. Pregnancy; verify status prior to initiation. Nursing mothers: not recommended.
Avoid live vaccines in immunocompromised. Concomitant adenosine deaminase inhibitors (eg, pentostatin): not recommended.
Anemia, thrombocytopenia, neutropenia, nausea, vomiting, diarrhea, constipation, fatigue, pyrexia, cough, dyspnea, somnolence, dizziness, peripheral neuropathy, hypoesthesia, headache, paresthesia; tumor lysis syndrome (monitor).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline